Sign In
Buy MOH
$200.34
+0.86 (+0.431%)
At Close: Jul 28, 2026
ATLANTA, Oct. 06, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH). The lawsuit alleges that D
LOS ANGELES--(BUSINESS WIRE)---- $STOCKS--Law Offices of Frank R. Cruz Encourages Molina Healthcare, Inc. (MOH) Shareholders To Inquire About Securities Fraud Class Action.
Do you own shares of MOH? Robbins LLP Informs Investors of the Molina Healthcare, Inc. Class Action Lawsuit
11:52pm, Friday, 03'rd Oct 2025
SAN DIEGO , Oct. 3, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Molina Healthcare, Inc. (
SAN DIEGO, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Molina Healthcare class action lawsuit seeks to represent purchasers or acquirers of Molina Healthcare,
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), announces that it has filed a class action lawsuit in the United States District Court for the Central District of California, ca
UnitedHealth vs. Molina: Who's Poised for the Healthiest Comeback?
10:46am, Friday, 26'th Sep 2025
The U.S. healthcare sector is navigating a turbulent landscape, shaped by rising medical costs, regulatory scrutiny and evolving patient behavior. Health insurers are under pressure as increasing util
CNC Stock or Molina Healthcare?
08:50am, Thursday, 25'th Sep 2025
After a period of underperformance, Centene's stock (NYSE:CNC) has recently seen a strong rebound, rising 6% on September 24 and nearly 20% over the last month. This follows a significant drop in July
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH
10:00am, Sunday, 14'th Sep 2025
NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH
10:00am, Saturday, 13'th Sep 2025
NEW YORK , Sept. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH
02:50pm, Wednesday, 10'th Sep 2025
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH). Such invest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH
03:30pm, Monday, 08'th Sep 2025
NEW YORK , Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. ("Molina" or the "Company") (NYSE: MOH).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Molina Healthcare, Inc. - MOH
10:00am, Saturday, 06'th Sep 2025
NEW YORK, Sept. 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Molina Healthcare, Inc. (“Molina” or the “Company”) (NYSE: MOH).
UnitedHealth price target raised to $362 from $337 at Barclays
06:24am, Thursday, 04'th Sep 2025
Barclays analyst Andrew Mok raised the firm's price target on UnitedHealth to $362 from $337 and keeps an Overweight rating on the shares. The firm adjusted estimates and targets in the managed care a
Molina Healthcare price target lowered to $185 from $186 at Barclays
06:24am, Thursday, 04'th Sep 2025
Barclays lowered the firm's price target on Molina Healthcare to $185 from $186 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and healthca
Humana price target raised to $325 from $275 at Barclays
06:24am, Thursday, 04'th Sep 2025
Barclays analyst Andrew Mok raised the firm's price target on Humana to $325 from $275 and keeps an Equal Weight rating on the shares. The firm adjusted estimates and targets in the managed care and h
